Pharmafile Logo
Pharmafocus logo
Advanced Search
novartis_outside_1

Novartis signs $150 million deal with Xencor to develop bispecific antibodies

June 28, 2016
Manufacturing and Production, Research and Development, Sales and Marketing Cancer, Novartis, Xencor, bispecific antibodies, deal, drug development, drug trial

Swiss drugmaker Novartis (VTX: NOVN) said it has signed a $150 million upfront collaboration and licensing agreement with Xencor to …

News
takeda_world

Takeda to return molecules/ products for Japan to Amgen

June 27, 2016
Manufacturing and Production, Research and Development, Sales and Marketing Amgen, Cancer, Japan, Takeda Pharmaceutical, drug development, drug trial

Japanese firm Takeda Pharmaceutical (TSE: 4502) said it will return the rights to develop and market multiple molecules/ products from …

News
gwpharma

GW Pharmaceuticals says Phase III trials for Epidiolex to treat rare epilepsy in children shows positive results

June 27, 2016
Research and Development, Sales and Marketing Epidiolex, GW Pharmaceuticals, NDA, US FDA, drug trial, orphan drug

GW Pharmaceuticals (Nasdaq: GWPH) said late-stage trials for its Epidiolex (cannabidiol or CBD) to treat Lennox-Gastaut syndrome (LGS), a rare …

News

Boehringer Ingelheim says Phase III trials for its Ofev slowed progression of fatal lung disease

June 27, 2016
Research and Development, Sales and Marketing Boehringer Ingelheim, drug trial, idiopathic pulmonary fibrosis, research

German drugmaker Boehringer Ingelheim said late-stage trials for its Ofev (nintedanib) to treat a fatal lung condition slowed progression of …

News

Sanofi, Boehringer Ingelheim sign definitive agreements for swap

June 27, 2016
Research and Development, Sales and Marketing Boehringer Ingelheim, Financial, Sanofi, business swap, merger and acquisition

French drugmaker Sanofi (Euronext: SAN) and German pharma firm Boehringer Ingelheim have signed a definitive agreement for a business swap announced …

News
stocks1

Weekly Movers: Lpath, Paratek, Inovio…

June 27, 2016
Research and Development, Sales and Marketing

Shares in Lpath (Nasdaq: LPTN) jumped 55% after the company said it has secured a two-year $1.45 million grant by …

Feature
china-pharmaceutical-industry

Brexit may also create opportunities for UK’s pharmaceutical and medical device industries – report

June 27, 2016
Research and Development, Sales and Marketing

Even though UK’s exit from the European Union undoubtedly creates significant issues for the UK pharmaceutical and medical device industries …

News

Woodley Equipment Company the Specialist Global Provider of Equipment for Clinical Trials exhibits at DIA 2016

June 24, 2016

Woodley Equipment Company the Specialist Global Provider of Equipment for Clinical Trials

News
Press release
astellas_imageuk

Astellas UK suspended from ABPI for “deception” and other cultural failings

June 24, 2016
Medical Communications, Research and Development, Sales and Marketing ABPI, Astellas, cultural failings

Astellas UK has been suspended as a member of the Association of the British Pharmaceutical Industry (ABPI) for a period …

News

Nice rejects AstraZeneca’s Tagrisso for lung cancer in preliminary recommendation

June 24, 2016
Medical Communications, Research and Development AstraZeneca, CDF, NICE, lung cancer, regulation

UK drugmaker AstraZeneca (LSE: AZN) said the National Institute for Health and Care Excellence (Nice) has rejected Tagrisso (osimertinib) to …

News
brexit

“Immediate challenges” for UK pharma post-Brexit, says ABPI

June 24, 2016
Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing ABPI, brexit

The UK life sciences industry has expressed dismay at the result of the EU referendum, but has pledged to work …

News
allergan

FDA approves expanded label for Allergan’s Avycaz

June 24, 2016
Medical Communications, Research and Development, Sales and Marketing Allergan, Avycaz, FDA, expanded label

Allergan (NYSE: FDA) has announced that the US Food and Drug Administration (FDA) has approved its supplemental new drug application …

News
cancer

Genmab’s CLL drug gets negative opinion from EMA committee

June 24, 2016
Medical Communications, Research and Development, Sales and Marketing Arzerra, CHMP, CLL, EMA, Genmab, blood cancer

Genmab A/S (Nasdaq Copenhagen: GEN) said its drug Arzerra (ofatumumab) received a negative opinion by the Committee for Medicinal Products …

News
celgene_1_02

Nice rejects Celgene’s drug to treat blood cancer

June 24, 2016
Medical Communications, Research and Development CDF, Celgene, NICE, Vidaza, blood cancer

The National Institute for Health and Care Excellence (Nice) rejected biotech firm Celgene’s (Nasdaq: CELG) Vidaza (azacitidine) to treat a …

News
sanofi_hq__boetie_hall

Sanofi to add future payments onto Medivation offer, according to reports

June 23, 2016
Research and Development, Sales and Marketing Medivation, Sanofi

Sanofi (NYSE: SNY) is considering adding future payments, tied to certain targets, to its proposed $9.3 billion takeover of US …

News
eu

EU referendum outcome will have major consequences for UK’s pharma sector – GlobalData

June 23, 2016
Medical Communications, Sales and Marketing EMA, GlobalData, Pharma sector, brexit, referendum

The outcome of today’s referendum on the UK’s continuing membership of the European Union (EU) will have major consequences for …

News

Biogen promotes Paul McKenzie to executive vice president

June 23, 2016

Biogen (Nasdaq: BIIB) has promoted Paul McKenzie to the role of executive vice president for pharmaceutical operations & technology, effective July …

Appointment
azhqlondonweb

AstraZeneca set to lose out on $80 million after US turns down flu vaccine

June 23, 2016
Sales and Marketing AstraZeneca, CDC, flu, flu vaccine

AstraZeneca has confirmed that its influenza vaccine, FluMist Quadrivalent, will not be used in the US during the 2016-17 flu …

News

Timely use of Novartis’ Entresto could prevent/delay over 28,000 US deaths a year – study

June 23, 2016
Research and Development, Sales and Marketing Entresto, JAMA Cardiology, Novartis, drug trial, research

A timely switch to Novartis’ (VTX: NOVN) heart failure drug Entresto (sacubitril/valsartan) in patients could prevent or delay more than …

News
humira_abbott_

New Humira data shows improved quality of life in ulcerative colitis patients

June 23, 2016
Research and Development AbbVie, Humira, data, ulcerative colitis

New data on Humira (adalimumab) has been presented at the British Society of Gastroenterology, demonstrating the drug’s efficacy and improvement …

News
The Gateway to Local Adoption Series

Latest content

SMC accepts amivantamab and lazertinib for EGFR-positive lung cancer

May 22, 2026

BioDuro and CTI Biotechnology in preclinical drug development partnership

May 21, 2026

Sygnature Discovery appoints Susanne Back as Head of In Vivo Pharmacology

May 21, 2026

NICE recommends sotatercept for pulmonary arterial hypertension

May 20, 2026

Vetter begins construction of new injectable medicines facility

May 20, 2026